![Douglas Eby](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Douglas Eby currently works at Cambridge Science Corp., as President, Chief Executive Officer & Director and Kyttaro Ltd., as Chief Executive Officer & Director.
Actieve functies van Douglas Eby
Bedrijven | Functie | Begin |
---|---|---|
Cambridge Science Corp.
![]() Cambridge Science Corp. BiotechnologyHealth Technology Cambridge Science Corp. engages in investing in the medicine. It also engages in improving patient lives through the acceleration of translational research and develops internal drug development programs. The firm finances and manages biotech companies commercializing novel technologies developed in the labs and the research institutions. The company was founded in 2017 and is headquartered in Cambridge, MA. | Algemeen Directeur | - |
KYTTARO Ltd.
![]() KYTTARO Ltd. BiotechnologyHealth Technology Kyttaro Ltd. develops monoclonal antibodies for potential treatment of atherosclerotic cardiovascular diseases. The company is based in Oxford, UK. The British company was founded in 2021. The CEO is Douglas Eby. | Algemeen Directeur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Cambridge Science Corp.
![]() Cambridge Science Corp. BiotechnologyHealth Technology Cambridge Science Corp. engages in investing in the medicine. It also engages in improving patient lives through the acceleration of translational research and develops internal drug development programs. The firm finances and manages biotech companies commercializing novel technologies developed in the labs and the research institutions. The company was founded in 2017 and is headquartered in Cambridge, MA. | Health Technology |
KYTTARO Ltd.
![]() KYTTARO Ltd. BiotechnologyHealth Technology Kyttaro Ltd. develops monoclonal antibodies for potential treatment of atherosclerotic cardiovascular diseases. The company is based in Oxford, UK. The British company was founded in 2021. The CEO is Douglas Eby. | Health Technology |